Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical
  • Published:

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen

British Journal of Cancer volume 86, pages 213–217 (2002)Cite this article

Abstract

Recently, we reported a highly active regimen in advanced gastric cancer including a weekly administration of cisplatin, epidoxorubicin, leucovorin, 5-fluorouracil with the support of filgrastim. In order to simplify the administration and to decrease the toxicity of these drugs, mainly epidoxorubicin-induced alopecia, we designed a regimen including an infusional 5-fluorouracil schedule according to the de Gramont regimen, cisplatin and mitomycin C replacing epidoxorubicin. Forty-five patients with advanced or metastatic gastric cancer were treated with cisplatin 50 mg m−2 i.v. on day 1, every 2 weeks, 6S-stereoisomer-leucovorin 100 mg m−2 i.v. followed by 5-fluorouracil 400 mg m−2 i.v. bolus and 600 mg m−2 i.v. in a 22-h infusion, on days 1 and 2, every 2 weeks, and mitomycin C 7 mg m−2 i.v. bolus on day 2, every 6 weeks. Grades 3–4 toxicities (National Cancer Institute-Common Toxicity Criteria) consisted mainly of neutropenia and thrombocytopenia. Five patients had a complete response and 16 had a partial response for an overall response rate of 46.7% (95% confidence interval, 32.1–61.2%). The median survival was 11 months. The combination of cisplatin, 5-fluorouracil and leucovorin according to de Gramont, and mitomycin C seems to be an active and safe regimen in the treatment of advanced gastric cancer. Because of its low cost it may be suggested for patients not enrolled into clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  • Arbuck SG, Douglass HO, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5: 1150–1156

    Article  CAS  Google Scholar 

  • Becker K, Rinas B, Widmann B, Heider A, Niederle N (1997) High-dose 5-fluorouracil/folinic acid (HD-5-FU/FA) plus mitomycin C (MMC) in patients with refractory colorectal cancer. Proc Am Soc Clin Oncol 16: 283a

    Google Scholar 

  • Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, Testa E, Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G, Cellerino R, Catalano G (1997) Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15: 3313–3319

    Article  CAS  Google Scholar 

  • Cascinu S, Labianca R, Graziano F, Pancera G, Barni S, Frontini L, Luporini G, Cellerino R, Catalano G (1998) Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 78: 390–393

    Article  CAS  Google Scholar 

  • de Gramont A, Bosset JF, Milan C, Rougier P, Bouchè O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 15: 808–815

    Article  CAS  Google Scholar 

  • Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A (1994) A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609–616

    Article  CAS  Google Scholar 

  • Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomised comparison between chemotherapy plus supportive cancer with best supportive care in advanced gastric cancer. Ann Oncol 8: 163–168

    Article  CAS  Google Scholar 

  • Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N, Cascinu S (2000) A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 11: 1263–1266

    Article  CAS  Google Scholar 

  • Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481

    Article  Google Scholar 

  • Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C, versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813–3818

    Article  CAS  Google Scholar 

  • Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83: 458–463

    Article  CAS  Google Scholar 

  • Kretzschmar A, Reichardt P, Thuss-Patience PC, Hohenberger P, Benter T, Dorken B, Kohne CH (2000) Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncology 59: 14–17

    Article  CAS  Google Scholar 

  • Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esteban P, Gracia JM, Buesa JM, Fernandez OA et al (1991) Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751–754

    Article  CAS  Google Scholar 

  • Leichman L, Berry BT (1991) Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 18: Suppl 3 25–33

    CAS  PubMed  Google Scholar 

  • Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, Souglakos J, Sarra E, Vardakis N, Hatzidaki D, Sarmonis G, Georgoulias V (2000) Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 23: 341–344

    Article  CAS  Google Scholar 

  • Mitry E, Artru P, Taieb J, Boige V, Vaillant JN, Clavero-Fabri MC, Lesur G, Dupuy P, Ducreux M, Rougier P (2000) Combination of leucovorin, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in the treatment of advanced upper gastrointestinal carcinomas (AUGIC). Ann Oncol 11: Suppl 4 65

    Google Scholar 

  • Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37–41

    Article  CAS  Google Scholar 

  • National Cancer Institute (1990) Guidelines for reporting of adverse drug reactions: Cancer therapy evaluation program. Washington, DC, National Cancer Institute,. 1–17

  • Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587–591

    Article  CAS  Google Scholar 

  • Ross P, Norman A, Cunningham D, Webb A, Ivesson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J (1997) A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995–1001

    Article  CAS  Google Scholar 

  • Ross P, Cunningham D, Scarffe H, Nicolson M, Seymour M, Harper P, Price T, Hill A, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (1999) Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. Eur J Cancer 35: Suppl 4 S137

    Article  Google Scholar 

  • Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11: 301–306

    Article  CAS  Google Scholar 

  • Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, Pignon JP, Elias D, Bellefqih S, Bognel C, Lusinchi A, Cvitkovic E, Droz JP (1994) Neoadjuvant chemotherapy in locally advanced gastric carcinoma-A phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 30A: 1269–1275

    Article  CAS  Google Scholar 

  • Schipper DL, Wagener DJT (1996) Chemotherapy of gastric cancer. Anticancer Drugs 7: 137–149

    Article  CAS  Google Scholar 

  • Schnall S, Macdonald JS (1993) Mitomycin therapy in gastric cancer. Oncology 50: Suppl 1 70–77

    Article  Google Scholar 

  • Simon R (1989) Optimal II stage designs for phase II clinical trials. Controlled Clin Trials 10: 1–10

    Article  CAS  Google Scholar 

  • Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. Br J Cancer 70: 380–383

    Article  CAS  Google Scholar 

  • Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648–2657

    Article  CAS  Google Scholar 

  • Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261–267

    Article  CAS  Google Scholar 

  • Wilke H, Korn M, Vanhoefer U, Fink U, Stahl M, Preusser P, Kohne CH, Klaassen U, Harstrick A, Schmoll HJ, Seeber S (1996) Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother 6: 123–126

    CAS  PubMed  Google Scholar 

  • Young RC (1990) Mechanism to improve chemotherapy effectiveness. Cancer 65: 815–822

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, V.le Gramsci 14, Parma, 43100, Italy

    S Cascinu & S Salvagni

  2. Department of Medical Oncology, Azienda Osp. S. Salvatore, Pesaro, 61100, Italy

    A M Baldelli, V Catalano, P Giordani & G Catalano

  3. Department of Medical Oncology, Ospedali Riuniti, L.go Barozzi 1, Bergamo, 24128, Italy

    G D Beretta & R Labianca

  4. Department of Medical Oncology, Ospedali E. Profili, Fabriano, 60044, AN, Italy

    R R Silva & D Mari

  5. Department of Medical Oncology, Azienda Osp. S. Filippo Neri, Rome, 00135, Italy

    G Gasparini

  6. Department of Medical Oncology, University of Messina, Messina, 98123, Italy

    R Maisano

  7. Department of Medical Oncology, Azienda Osp. Treviglio-Caravaggio, P.le Ospedale 1, Treviglio, 24047, BG, Italy

    S Barni

  8. Department of Medical Oncology, S. Paolo Hospital, Milan, 20100, Italy

    L Frontini

  9. Coordinating Data Center GISCAD, Milan, 20100, Italy

    C Curti

Authors
  1. S Cascinu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A M Baldelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Giordani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G D Beretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R R Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Gasparini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Mari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Maisano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Salvagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Barni
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Labianca
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. L Frontini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. C Curti
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Cascinu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cascinu, S., Baldelli, A., Catalano, V. et al. Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen. Br J Cancer 86, 213–217 (2002). https://doi.org/10.1038/sj.bjc.6600046

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bjc.6600046

Keywords

This article is cited by

Search

Advanced search

Quick links